Based	O
on	O
its	O
minimal	O
extent	O
of	O
absorption	O
interactions	O
of	O
PROTOPIC	B-Brand
Ointment	O
with	O
systemically	O
administered	O
drugs	O
are	O
unlikely	O
to	O
occur	O
but	O
can	O
not	O
be	O
ruled	O
out	O
.	O
      
Formal	O
topical	O
drug	O
interaction	O
studies	O
with	O
PROTOPIC	B-Brand
Ointment	O
have	O
not	O
been	O
conducted	O
.	O
      
Some	O
examples	O
of	O
such	O
drugs	O
are	O
erythromycin	B-Drug
itraconazole	B-Drug
ketoconazole	B-Drug
fluconazole	B-Drug
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
cimetidine	B-Drug
.	O
      
The	O
concomitant	O
administration	O
of	O
known	O
CYP9A9	O
inhibitors	O
in	O
patients	O
with	O
widespread	O
and	O
/	O
or	O
erythrodermic	O
disease	O
should	O
be	O
done	O
with	O
caution	O
.	O
      
Alcohol	B-Drug
(	O
this	O
combination	O
may	O
make	O
you	O
very	O
sick	O
)	O
and	O
primaquine	B-Drug
      
Interactions	O
Interaction	O
may	O
occur	O
with	O
Antacids	B-Group
Calcium	B-Drug
supplements	O
Cholestyramine	B-Drug
Choline	B-Drug
and	O
magnesium	B-Drug
salicylates	I-Drug
Colestipol	B-Drug
Iron	B-Drug
-	O
containing	O
drugs	O
Laxatives	B-Group
Magnesium	B-Drug
salicylate	I-Drug
:	O
these	O
drugs	O
may	O
decrease	O
the	O
potency	O
of	O
tetracyclines	B-Group
.	O
      
No	O
specific	O
interactions	O
are	O
known	O
at	O
this	O
time	O
.	O
      
Drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
LUCENTIS	B-Brand
.	O
      
No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Vectibix	B-Brand
.	O
      
Drug	O
/	O
Laboratory	O
Interactions	O
:	O
There	O
have	O
been	O
no	O
formal	O
drug	O
interaction	O
studies	O
performed	O
with	O
RITUXAN	B-Brand
.	O
      
Concomitant	O
Therapy	O
Special	O
care	O
should	O
be	O
exercised	O
in	O
treating	O
patients	O
who	O
are	O
receiving	O
concomitant	O
therapy	O
(	O
either	O
topically	O
or	O
systemically	O
)	O
with	O
known	O
photosensitizing	O
agents	O
such	O
as	O
anthralin	B-Drug
coal	B-Drug_n
tar	I-Drug_n
or	O
coal	B-Drug_n
tar	I-Drug_n
derivatives	I-Drug_n
griseofulvin	B-Drug
phenothiazines	B-Group
nalidixic	B-Drug
acid	I-Drug
halogenated	B-Group
salicylanilides	I-Group
(	O
bacteriostatic	O
soaps	O
)	O
sulfonamides	B-Drug
tetracyclines	B-Group
thiazides	B-Group
and	O
certain	O
organic	O
staining	O
dyes	O
such	O
as	O
methylene	B-Drug_n
blue	I-Drug_n
toluidine	B-Drug_n
blue	I-Drug_n
rose	O
bengal	O
and	O
methyl	O
orange	O
.	O
      
In	O
controlled	O
clinical	O
trials	O
ALOXI	B-Brand
injection	O
has	O
been	O
safely	O
administered	O
with	O
corticosteroids	B-Group
analgesics	B-Group
antiemetics	B-Group
/	O
antinauseants	B-Group
antispasmodics	B-Group
and	O
anticholinergic	B-Group
agents	I-Group
.	O
      
Palonosetron	B-Drug
did	O
not	O
inhibit	O
the	O
antitumor	O
activity	O
of	O
the	O
five	O
chemotherapeutic	B-Group
agents	I-Group
tested	O
(	O
cisplatin	B-Drug
cyclophosphamide	B-Drug
cytarabine	B-Drug
doxorubicin	B-Drug
and	O
mitomycin	B-Drug
C	I-Drug
)	O
in	O
murine	O
tumor	O
models	O
.	O
      
Palonosetron	B-Drug
is	O
eliminated	O
from	O
the	O
body	O
through	O
both	O
renal	O
excretion	O
and	O
metabolic	O
pathways	O
with	O
the	O
latter	O
mediated	O
via	O
multiple	O
CYP	O
enzymes	O
.	O
      
In	O
vitro	O
studies	O
indicated	O
that	O
palonosetron	B-Drug
is	O
not	O
an	O
inhibitor	O
of	O
CYP9A9	O
CYP9A9	O
CYP9B9	O
CYP9C9	O
CYP9D9	O
CYP9E9	O
and	O
CYP9A9	O
/	O
9	O
(	O
CYP9C9	O
was	O
not	O
investigated	O
)	O
nor	O
does	O
it	O
induce	O
the	O
activity	O
of	O
CYP9A9	O
CYP9D9	O
or	O
CYP9A9	O
/	O
9	O
.	O
      
Therefore	O
the	O
potential	O
for	O
clinically	O
significant	O
drug	O
interactions	O
with	O
palonosetron	B-Drug
appears	O
to	O
be	O
low	O
.	O
      
Potential	O
drug	O
interactions	O
between	O
OXISTAT	B-Brand
and	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
Although	O
no	O
drug	O
/	O
drug	O
interactions	O
were	O
discovered	O
during	O
the	O
clinical	O
trials	O
of	O
MARINOL	B-Brand
Capsules	O
cannabinoids	B-Group
may	O
interact	O
with	O
other	O
medications	O
through	O
both	O
metabolic	O
and	O
pharmacodynamic	O
mechanisms	O
.	O
      
Two	O
early	O
clinical	O
studies	O
conducted	O
in	O
patients	O
who	O
received	O
Macugen	B-Brand
alone	O
and	O
in	O
combination	O
with	O
PDT	O
revealed	O
no	O
apparent	O
difference	O
in	O
the	O
plasma	O
pharmacokinetics	O
of	O
pegaptanib	B-Drug
.	O
      
Interactions	O
for	O
Dronabinol	B-Drug
:	O
In	O
studies	O
involving	O
patients	O
with	O
AIDS	O
and	O
/	O
or	O
cancer	O
MARINOL	B-Brand
(	O
Dronabinol	B-Drug
)	O
Capsules	O
has	O
been	O
co	O
-	O
administered	O
with	O
a	O
variety	O
of	O
medications	O
(	O
e.g.	O
cytotoxic	O
agents	O
anti	B-Drug
-	O
infective	I-Drug
agents	O
sedatives	B-Group
or	O
opioid	B-Group
analgesics	I-Group
)	O
without	O
resulting	O
in	O
any	O
clinically	O
significant	O
drug	O
/	O
drug	O
interactions	O
.	O
      
The	O
concomitant	O
administration	O
of	O
known	O
CYP9A	O
family	O
of	O
inhibitors	O
in	O
patients	O
with	O
widespread	O
and	O
/	O
or	O
erythrodermic	O
disease	O
should	O
be	O
done	O
with	O
caution	O
.	O
      
Some	O
examples	O
of	O
such	O
drugs	O
are	O
erythromycin	B-Drug
itraconazole	B-Drug
ketoconazole	B-Drug
fluconazole	B-Drug
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
cimetidine	B-Drug
.	O
      
Potential	O
interactions	O
between	O
Elidel	B-Brand
and	O
other	O
drugs	O
including	O
immunizations	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
Due	O
to	O
the	O
very	O
low	O
blood	O
levels	O
of	O
pimecrolimus	B-Drug
detected	O
in	O
some	O
patients	O
after	O
topical	O
application	O
systemic	O
drug	O
interactions	O
are	O
not	O
expected	O
but	O
can	O
not	O
be	O
ruled	O
out	O
.	O
      
Since	O
there	O
is	O
no	O
interaction	O
with	O
theophylline	B-Drug
interaction	O
with	O
other	O
methylxanthines	B-Group
such	O
as	O
caffeine	B-Drug
is	O
unlikely	O
.	O
      
However	O
renal	O
toxicity	O
was	O
seen	O
with	O
this	O
drug	O
in	O
combination	O
with	O
cisplatin	B-Drug
in	O
clinical	O
trials	O
.	O
      
Digoxin	B-Drug
:	O
Sparfloxacin	B-Drug
has	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O
      
Methylxanthines	B-Group
:	O
Sparfloxacin	B-Drug
does	O
not	O
increase	O
plasma	O
theophylline	B-Drug
concentrations	O
.	O
      
Although	O
this	O
displacement	O
has	O
not	O
been	O
confirmed	O
in	O
vivo	O
practitioners	O
should	O
monitor	O
patients	O
for	O
a	O
change	O
in	O
dosage	O
requirements	O
when	O
administering	O
dronabinol	B-Drug
to	O
patients	O
receiving	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
.	O
      
Dronabinol	B-Drug
is	O
highly	O
protein	O
bound	O
to	O
plasma	O
proteins	O
and	O
therefore	O
might	O
displace	O
other	O
protein	O
-	O
bound	O
drugs	O
.	O
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
sparfloxacin	B-Drug
.	O
      
The	O
oral	O
bioavailability	O
of	O
sparfloxacin	B-Drug
is	O
not	O
reduced	O
when	O
the	O
aluminum	B-Drug
-	O
magnesium	B-Drug
suspension	O
is	O
administered	O
9	O
hours	O
following	O
sparfloxacin	O
administration	O
.	O
      
Zinc	B-Drug
/	O
iron	B-Drug
salts	O
:	O
Absorption	O
of	O
quinolones	B-Group
is	O
reduced	O
significantly	O
by	O
these	O
preparations	O
.	O
      
These	O
products	O
may	O
be	O
taken	O
9	O
hours	O
after	O
sparfloxacin	B-Drug
administration	O
.	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
does	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
sparfloxacin	B-Drug
.	O
      
However	O
because	O
telbivudine	B-Drug
is	O
eliminated	O
primarily	O
by	O
renal	O
excretion	O
co	O
administration	O
of	O
telbivudine	B-Drug
with	O
drugs	O
that	O
alter	O
renal	O
function	O
may	O
alter	O
plasma	O
concentrations	O
of	O
telbivudine	B-Drug
.	O
      
Telbivudine	B-Drug
is	O
excreted	O
mainly	O
by	O
passive	O
diffusion	O
so	O
the	O
potential	O
for	O
interactions	O
between	O
telbivudine	B-Drug
and	O
other	O
drugs	O
eliminated	O
by	O
renal	O
excretion	O
is	O
low	O
.	O
      
Caution	O
is	O
indicated	O
when	O
Aredia	B-Brand
is	O
used	O
with	O
other	O
potentially	O
nephrotoxic	O
drugs	O
.	O
      
Therefore	O
furosemide	B-Drug
should	O
not	O
be	O
administered	O
in	O
intravenous	O
lines	O
containing	O
PRIMACOR	B-Brand
.	O
      
Chemical	O
Interactions	O
There	O
is	O
an	O
immediate	O
chemical	O
interaction	O
which	O
is	O
evidenced	O
by	O
the	O
formation	O
of	O
a	O
precipitate	O
when	O
furosemide	B-Drug
is	O
injected	O
into	O
an	O
intravenous	O
line	O
of	O
an	O
infusion	O
of	O
PRIMACOR	B-Brand
.	O
      
May	O
interact	O
with	O
cimetidine	B-Drug
digoxin	B-Drug
medicines	O
to	O
control	O
heart	O
rhythm	O
sevelamer	B-Drug
and	O
theophylline	B-Drug
.	O
      
The	O
interaction	O
may	O
result	O
from	O
reduced	O
absorption	O
of	O
phenytoin	B-Drug
and	O
an	O
increase	O
in	O
the	O
rate	O
of	O
its	O
metabolism	O
and	O
elimination	O
.	O
      
captopril	B-Drug
;	O
      
chlorthalidone	B-Drug
furosemide	B-Drug
hydrochlorothiazide	B-Drug
spironolactone	B-Drug
;	O
      
and	O
potassium	B-Drug
supplements	O
.	O
      
heparin	B-Drug
warfarin	B-Drug
diazepam	B-Drug
insulin	B-Drug
;	O
      
Twelve	O
of	O
9	O
(	O
9	O
%	O
)	O
patients	O
developed	O
serious	O
intraocular	O
inflammation	O
;	O
      
in	O
9	O
of	O
the	O
9	O
patients	O
this	O
occurred	O
when	O
LUCENTIS	B-Brand
was	O
administered	O
9	O
days	O
(	O
9	O
days	O
)	O
after	O
verteporfin	B-Drug
PDT	O
.	O
      
isosorbide	B-Drug
dinitrate	I-Drug
nitroglycerin	B-Drug
;	O
      
hydralazine	B-Drug
prazosin	B-Drug
;	O
      
-	O
Antacids	B-Group
-	O
Diarrhea	O
medicine	O
containing	O
kaolin	B-Drug
or	O
attapulgite	B-Drug
-	O
Ketoconazole	B-Drug
-	O
Central	B-Group
nervous	I-Group
system	I-Group
CNS	I-Group
depressants	I-Group
-	O
Other	O
anticholinergics	B-Group
-	O
Tricyclic	B-Group
antidepressants	I-Group
(	O
e.g.	O
Elavil	B-Brand
Asendin	B-Brand
Anafranil	B-Brand
Pertofrane	B-Brand
Sinequan	B-Brand
Tofranil	B-Brand
Aventyl	B-Brand
Surmontil	B-Brand
)	O
-	O
Potassium	B-Drug
chloride	I-Drug
(	O
e.g.	O
Kay	B-Brand
Ciel	I-Brand
)	O
      
Drug	O
Interactions	O
:	O
Pirenzepine	B-Drug
may	O
interact	O
with	O
the	O
following	O
drugs	O
which	O
may	O
affect	O
the	O
effect	O
of	O
Pirenzepine	B-Drug
or	O
whose	O
effects	O
may	O
be	O
affected	O
.	O
      
Consult	O
your	O
doctor	O
or	O
pharmacist	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
:	O
seizure	O
medications	O
antibiotics	B-Group
warfarin	B-Drug
medications	O
to	O
help	O
you	O
sleep	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
:	O
The	O
concomitant	O
use	O
of	O
anticholinergic	B-Group
agents	I-Group
may	O
make	O
patients	O
hyporesponsive	O
i.e	O
.	O
      
may	O
produce	O
a	O
false	O
positive	O
result	O
.	O
      
Talk	O
to	O
your	O
pharmacist	O
for	O
more	O
information	O
.	O
      
Drug	O
Interactions	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
This	O
medicine	O
may	O
be	O
affected	O
by	O
the	O
drug	O
cholestyramine	B-Drug
and	O
should	O
not	O
be	O
taken	O
with	O
any	O
form	O
of	O
estrogen	O
therapy	O
.	O
      
If	O
you	O
are	O
taking	O
these	O
medicines	O
together	O
or	O
you	O
have	O
further	O
questions	O
about	O
drug	O
interactions	O
talk	O
to	O
your	O
doctor	O
or	O
pharmacist	O
.	O
      
Drugs	O
that	O
may	O
decrease	O
the	O
effects	O
of	O
this	O
medicine	O
include	O
:	O
Rifampin	B-Drug
barbiturates	B-Group
phenytoin	B-Drug
(	O
Dilantin	B-Brand
)	O
carbamazepine	B-Drug
(	O
Tegretol	B-Brand
)	O
Estrogens	B-Group
may	O
decrease	O
the	O
effects	O
of	O
benzodiazepines	B-Group
(	O
lorezepam	B-Drug
oxezepam	B-Drug
temezepam	B-Drug
)	O
.	O
      
There	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
of	O
PHOTOFRIN	B-Brand
and	O
any	O
other	O
drugs	O
.	O
      
However	O
it	O
is	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
photosensitizing	B-Group
agents	I-Group
(	O
e.g.	O
tetracyclines	B-Group
sulfonamides	B-Group
phenothiazines	B-Group
sulfonylurea	B-Group
hypoglycemia	O
agents	O
thiazide	B-Group
diuretics	I-Group
and	O
griseofulvin	B-Drug
)	O
could	O
increase	O
the	O
photosensitivity	O
reaction	O
.	O
      
PHOTOFRIN	B-Brand
PDT	O
causes	O
direct	O
intracellular	O
damage	O
by	O
initiating	O
radical	O
chain	O
reactions	O
that	O
damage	O
intracellular	O
membranes	O
and	O
mitochondria	O
.	O
      
Tissue	O
damage	O
also	O
results	O
from	O
ischemia	O
secondary	O
to	O
vasoconstriction	O
platelet	O
activation	O
and	O
aggregation	O
and	O
clotting	O
.	O
      
Research	O
in	O
animals	O
and	O
in	O
cell	O
culture	O
has	O
suggested	O
that	O
many	O
drugs	O
could	O
influence	O
the	O
effects	O
of	O
PDT	O
possible	O
examples	O
of	O
which	O
are	O
described	O
below	O
.	O
      
There	O
are	O
no	O
human	O
data	O
that	O
support	O
or	O
rebut	O
these	O
possibilities	O
.	O
      
Compounds	O
that	O
quench	O
active	O
oxygen	O
species	O
or	O
scavenge	O
radicals	O
such	O
as	O
dimethyl	B-Drug_n
sufloxide	I-Drug_n
b	B-Drug
-	O
carotene	I-Drug
ethanol	B-Drug
formate	B-Drug_n
and	O
mannitol	B-Drug
would	O
be	O
expected	O
to	O
decrease	O
PDT	O
activity	O
.	O
      
No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
.	O
      
Drugs	O
that	O
decrease	O
clotting	O
vasoconstriction	O
or	O
platelet	O
aggregation	O
e.g.	O
thromboxane	O
A9	O
inhibitors	O
could	O
decrease	O
the	O
efficacy	O
of	O
PDT	O
.	O
      
Glucocorticoid	B-Group
hormones	O
given	O
before	O
or	O
concomitant	O
with	O
PDT	O
may	O
decrease	O
the	O
efficacy	O
of	O
the	O
treatment	O
.	O
      
Preclinical	O
data	O
also	O
suggest	O
that	O
tissue	O
ischemia	O
allopurinol	B-Drug
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
some	O
prostaglandin	O
synthesis	O
inhibitors	O
could	O
interfere	O
with	O
PHOTOFRIN	O
PDT	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Infergen	B-Brand
.	O
      
Infergen	B-Brand
should	O
be	O
used	O
cautiously	O
in	O
patients	O
who	O
are	O
receiving	O
agents	O
that	O
are	O
known	O
to	O
cause	O
myelosuppression	O
or	O
with	O
agents	O
known	O
to	O
be	O
metabolized	O
via	O
the	O
cytochrome	O
P	O
-	O
9	O
pathway.9	O
Patients	O
taking	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
pathway	O
should	O
be	O
monitored	O
closely	O
for	O
changes	O
in	O
the	O
therapeutic	O
and	O
/	O
or	O
toxic	O
levels	O
of	O
concomitant	O
drugs	O
.	O
      
However	O
formal	O
drug	O
interactions	O
studies	O
have	O
not	O
been	O
conducted	O
.	O
      
Concomitant	O
glucocorticoid	O
therapy	O
may	O
inhibit	O
the	O
response	O
to	O
Geref	B-Brand
.	O
There	O
was	O
no	O
evidence	O
in	O
the	O
controlled	O
studies	O
of	O
Geref	B-Brand
's	O
interaction	O
with	O
drugs	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
routine	O
pediatric	O
problems	O
/	O
illnesses	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Administration	O
of	O
the	O
BEXXAR	B-Brand
therapeutic	O
regimen	O
may	O
result	O
in	O
the	O
development	O
of	O
human	O
anti	O
-	O
murine	O
antibodies	O
(	O
HAMA	O
)	O
.	O
      
The	O
presence	O
of	O
HAMA	O
may	O
affect	O
the	O
accuracy	O
of	O
the	O
results	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
diagnostic	O
tests	O
and	O
may	O
affect	O
the	O
toxicity	O
profile	O
and	O
efficacy	O
of	O
therapeutic	O
agents	O
that	O
rely	O
on	O
murine	O
antibody	O
technology	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
Due	O
to	O
the	O
frequent	O
occurrence	O
of	O
severe	O
and	O
prolonged	O
thrombocytopenia	O
the	O
potential	O
benefits	O
of	O
medications	O
that	O
interfere	O
with	O
platelet	O
function	O
and	O
/	O
or	O
anticoagulation	O
should	O
be	O
weighed	O
against	O
the	O
potential	O
increased	O
risk	O
of	O
bleeding	O
and	O
hemorrhage	O
.	O
      
Therefore	O
warfarin	B-Drug
dose	O
changes	O
and	O
monitoring	O
for	O
the	O
effects	O
of	O
warfarin	B-Drug
on	O
blood	O
clotting	O
are	O
necessary	O
.	O
      
Patients	O
who	O
are	O
HAMA	O
positive	O
may	O
be	O
at	O
increased	O
risk	O
for	O
serious	O
allergic	O
reactions	O
and	O
other	O
side	O
effects	O
if	O
they	O
undergo	O
in	O
vivo	O
diagnostic	O
testing	O
or	O
treatment	O
with	O
murine	B-Group
monoclonal	I-Group
antibodies	I-Group
.	O
      
Heparin	B-Drug
should	O
not	O
be	O
included	O
in	O
the	O
same	O
syringe	O
as	O
Sodium	B-Drug
Tetradecyl	I-Drug
Sulfate	I-Drug
since	O
the	O
two	O
are	O
incompatible	O
.	O
      
The	O
physician	O
must	O
use	O
judgment	O
and	O
evaluate	O
any	O
patient	O
taking	O
antiovulatory	O
drugs	O
prior	O
to	O
initiating	O
treatment	O
with	O
Sotradecol	B-Brand
.	O
      
Interactions	O
for	O
Sodium	B-Drug
Tetradecyl	I-Drug
Sulfate	I-Drug
:	O
No	O
well	O
-	O
controlled	O
studies	O
have	O
been	O
performed	O
on	O
patients	O
taking	O
antiovulatory	O
agents	O
.	O
      
In	O
Trial	O
9	O
the	O
proportions	O
of	O
patients	O
in	O
the	O
placebo	O
and	O
Synagis	B-Brand
groups	O
who	O
received	O
routine	O
childhood	O
vaccines	B-Group
influenza	B-Group
vaccine	I-Group
bronchodilators	B-Group
or	O
corticosteroids	B-Group
were	O
similar	O
and	O
no	O
incremental	O
increase	O
in	O
adverse	O
reactions	O
was	O
observed	O
among	O
patients	O
receiving	O
these	O
agents	O
.	O
      
The	O
pharmacokinetic	O
profile	O
of	O
temazepam	B-Drug
does	O
not	O
appear	O
to	O
be	O
altered	O
by	O
orally	O
administered	O
cimetidine	B-Drug
dosed	O
according	O
to	O
labeling	O
.	O
      
TERAZOL	B-Brand
9	O
Vaginal	O
Cream	O
9	O
%	O
and	O
TERAZOL	B-Brand
9	O
Vaginal	O
Suppositories	O
9	O
mg	O
The	O
therapeutic	O
effect	O
of	O
these	O
products	O
is	O
not	O
affected	O
by	O
oral	O
contraceptive	B-Group
usage	O
.	O
      
TERAZOL	B-Brand
9	O
Vaginal	O
Cream	O
9	O
%	O
The	O
levels	O
of	O
estradiol	B-Drug
(	O
E9	O
)	O
and	O
progesterone	B-Drug
did	O
not	O
differ	O
significantly	O
when	O
9	O
%	O
terconazole	B-Drug
vaginal	O
cream	O
was	O
administered	O
to	O
healthy	O
female	O
volunteers	O
established	O
on	O
a	O
low	O
dose	O
oral	O
contraceptive	B-Group
.	O
      
Drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
Macugen	B-Brand
.	O
      
There	O
are	O
as	O
yet	O
no	O
known	O
drug	O
interactions	O
but	O
further	O
study	O
is	O
required	O
.	O
      
No	O
data	O
are	O
available	O
regarding	O
interaction	O
of	O
BILTRICIDE	B-Brand
with	O
other	O
drugs	O
.	O
      
This	O
medicine	O
is	O
generally	O
safe	O
with	O
other	O
medications	O
but	O
patient	O
should	O
consult	O
doctor	O
or	O
pharmacist	O
if	O
patient	O
is	O
taking	O
a	O
blood	O
thinner	O
(	O
anticoagulant	B-Group
)	O
cyclosporin	B-Drug
phenytoin	B-Drug
or	O
methotrexate	B-Drug
.	O
      
Because	O
systemic	O
exposure	O
to	O
Valstar	B-Brand
is	O
negligible	O
following	O
intravesical	O
administration	O
the	O
potential	O
for	O
drug	O
interactions	O
is	O
low	O
.	O
      
Maternal	O
sinus	O
bradycardia	O
with	O
abnormal	O
atrioventricular	O
rhythms	O
has	O
also	O
been	O
noted	O
when	O
oxytocin	B-Drug
was	O
used	O
concomitantly	O
with	O
cyclopropane	O
anesthesia	O
.	O
      
Misoprostol	B-Drug
does	O
not	O
exert	O
clinically	O
significant	O
effects	O
on	O
the	O
absorption	O
blood	O
levels	O
and	O
anti	O
-	O
platelet	O
effects	O
of	O
therapeutic	O
doses	O
of	O
aspirin	B-Brand
.	O
      
9	O
      
Pyrazinamide	B-Drug
has	O
been	O
reported	O
to	O
interfere	O
with	O
ACETEST	O
and	O
KETOSTIX	O
urine	O
tests	O
to	O
produce	O
a	O
pink	O
-	O
brown	O
color	O
.	O
      
Severe	O
hypertension	O
has	O
been	O
reported	O
when	O
oxytocin	B-Drug
was	O
given	O
three	O
to	O
four	O
hours	O
following	O
prophylactic	O
administration	O
of	O
a	O
vasoconstrictor	B-Group
in	O
conjunction	O
with	O
caudal	O
block	O
anesthesia	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Potential	O
interactions	O
between	O
ERTACZOTM	B-Brand
Cream	O
9	O
%	O
and	O
other	O
drugs	O
or	O
laboratory	O
tests	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
Combined	O
usage	O
of	O
MAO	B-Group
inhibitors	I-Group
should	O
be	O
avoided	O
      
Cyclopropane	O
anesthesia	O
may	O
modify	O
oxytocin	B-Drug
cardiovascular	O
effects	O
so	O
as	O
to	O
produce	O
unexpected	O
results	O
such	O
as	O
hypotension	O
.	O
      
thus	O
interactions	O
with	O
drugs	O
that	O
inhibit	O
induce	O
or	O
are	O
metabolized	O
by	O
those	O
enzymes	O
are	O
not	O
expected	O
.	O
      
Olmesartan	B-Drug
medoxomil	I-Drug
is	O
not	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
and	O
has	O
no	O
effects	O
on	O
P9	O
enzymes	O
;	O
      
The	O
bioavailability	O
of	O
olmesartan	B-Drug
was	O
not	O
significantly	O
altered	O
by	O
the	O
co	O
-	O
administration	O
of	O
antacids	B-Group
[	O
Al	O
(	O
OH	O
)	O
9	O
/	O
Mg	O
(	O
OH	O
)	O
9	O
]	O
.	O
      
No	O
significant	O
drug	O
interactions	O
were	O
reported	O
in	O
studies	O
in	O
which	O
olmesartan	B-Drug
medoxomil	I-Drug
was	O
co	O
-	O
administered	O
with	O
digoxin	B-Drug
or	O
warfarin	B-Drug
in	O
healthy	O
volunteers	O
.	O
      
There	O
are	O
so	O
far	O
no	O
reported	O
adverse	O
interactions	O
with	O
SAMe	B-Drug
and	O
other	O
drugs	O
dietary	O
supplements	O
or	O
foods	O
.	O
      
A	O
study	O
in	O
healthy	O
volunteers	O
involving	O
single	O
-	O
dose	O
IV	O
palonosetron	B-Drug
(	O
9	O
mg	O
)	O
and	O
steady	O
state	O
oral	O
metoclopramide	B-Drug
(	O
9	O
mg	O
four	O
times	O
daily	O
)	O
demonstrated	O
no	O
significant	O
pharmacokinetic	O
interaction	O
.	O
      
Remifentanil	B-Drug
clearance	O
is	O
not	O
altered	O
by	O
concomitant	O
administration	O
of	O
thiopental	B-Drug
isoflurane	B-Drug
propofol	B-Drug
or	O
temazepam	B-Drug
during	O
anesthesia	O
.	O
      
In	O
animals	O
the	O
duration	O
of	O
muscle	O
paralysis	O
from	O
succinylcholine	B-Drug
is	O
not	O
prolonged	O
by	O
remifentanil	B-Drug
.	O
      
In	O
vitro	O
studies	O
with	O
atracurium	B-Drug
mivacurium	B-Drug
esmolol	B-Drug
echothiophate	B-Drug
neostigmine	B-Drug
physostigmine	B-Drug
and	O
midazolam	B-Drug
revealed	O
no	O
inhibition	O
of	O
remifentanil	B-Drug
hydrolysis	O
in	O
whole	O
human	O
blood	O
by	O
these	O
drugs	O
.	O
      
Drug	O
-	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
VIGAMOX	B-Brand
solution	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
moxifloxacin	B-Drug
does	O
not	O
inhibit	O
CYP9A9	O
CYP9D9	O
CYP9C9	O
CYP9C9	O
or	O
CYP9A9	O
indicating	O
that	O
moxifloxacin	B-Drug
is	O
unlikely	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
drugs	O
metabolized	O
by	O
these	O
cytochrome	O
P9	O
isozymes	O
.	O
      
Clinical	O
studies	O
of	O
interactions	O
of	O
VIRAZOLE	B-Brand
with	O
other	O
drugs	O
commonly	O
used	O
to	O
treat	O
infants	O
with	O
RSV	O
infections	O
such	O
as	O
digoxin	B-Drug
bronchodilators	B-Group
other	O
antiviral	B-Group
agents	I-Group
antibiotics	B-Group
or	O
anti	B-Group
-	O
metabolites	I-Group
have	O
not	O
been	O
conducted	O
.	O
      
Interference	O
by	O
VIRAZOLE	B-Brand
with	O
laboratory	O
tests	O
has	O
not	O
been	O
evaluated	O
.	O
      
Misoprostol	B-Drug
has	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
kinetics	O
of	O
diclofenac	B-Drug
or	O
ibuprofen	B-Drug
.	O
      
Interactions	O
with	O
cylcopholsphamide	O
fludarabine	B-Drug
and	O
vidarabine	B-Drug
      
In	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
suggested	O
that	O
pioglitazone	B-Drug
may	O
be	O
a	O
weak	O
inducer	O
of	O
CYP	O
9	O
isoform	O
9A9	O
substrate	O
.	O
      
Pegaptanib	B-Drug
is	O
metabolized	O
by	O
nucleases	O
and	O
is	O
generally	O
not	O
affected	O
by	O
the	O
cytochrome	O
P9	O
system	O
.	O
      
lidocaine	B-Drug
quinidine	B-Drug
;	O
      
No	O
untoward	O
clinical	O
manifestations	O
have	O
been	O
observed	O
in	O
limited	O
experience	O
with	O
patients	O
in	O
whom	O
PRIMACOR	B-Brand
was	O
used	O
concurrently	O
with	O
the	O
following	O
drugs	O
:	O
digitalis	B-Group
glycosides	I-Group
;	O
      
-	O
Increased	O
action	O
of	O
oral	O
anticoagulants	B-Group
.	O
      
-	O
Decreased	O
absorption	O
of	O
colestipol	B-Drug
cholestyramine	B-Drug
mineral	B-Drug
oil	I-Drug
and	O
sucralfate	B-Drug
.	O
      
False	O
-	O
positive	O
tests	O
may	O
occur	O
in	O
patients	O
with	O
hypertension	O
without	O
pheochromocytoma	O
.	O
      
Misoprostol	B-Drug
has	O
not	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
beneficial	O
effects	O
of	O
aspirin	B-Brand
on	O
signs	O
and	O
symptoms	O
of	O
rheumatoid	O
arthritis	O
.	O
      
Diagnosis	O
of	O
pheochromocytoma	O
-	O
phentolamine	O
blocking	O
test	O
.	O
      
The	O
test	O
is	O
most	O
reliable	O
in	O
detecting	O
pheochromocytoma	O
in	O
patients	O
with	O
sustained	O
hypertension	O
and	O
least	O
reliable	O
in	O
those	O
with	O
paroxysmal	O
hypertension	O
.	O
      
To	O
date	O
post	O
-	O
marketing	O
experience	O
has	O
not	O
revealed	O
any	O
significant	O
drug	O
interactions	O
in	O
patients	O
who	O
have	O
received	O
NOVANTRONE	B-Brand
for	O
treatment	O
of	O
cancer	O
.	O
      
Mitoxantrone	B-Drug
and	O
its	O
metabolites	O
are	O
excreted	O
in	O
bile	O
and	O
urine	O
but	O
it	O
is	O
not	O
known	O
whether	O
the	O
metabolic	O
or	O
excretory	O
pathways	O
are	O
saturable	O
may	O
be	O
inhibited	O
or	O
induced	O
or	O
if	O
mitoxantrone	B-Drug
and	O
its	O
metabolites	O
undergo	O
enterohepatic	O
circulation	O
.	O
      
Following	O
concurrent	O
administration	O
of	O
NOVANTRONE	B-Brand
with	O
corticosteroids	B-Group
no	O
evidence	O
of	O
drug	O
interactions	O
has	O
been	O
observed	O
.	O
      
Information	O
on	O
drug	O
interactions	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
is	O
limited	O
.	O
      
Therefore	O
clinical	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
human	O
cytochrome	O
P9	O
isoenzymes	O
are	O
not	O
expected	O
.	O
      
An	O
additional	O
clinical	O
drug	O
-	O
drug	O
interaction	O
study	O
showed	O
no	O
effect	O
of	O
rifaximin	B-Drug
on	O
the	O
presystemic	O
metabolism	O
of	O
an	O
oral	O
contraceptive	B-Group
containing	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
norgestimate	B-Drug
.	O
      
Drug	O
-	O
Drug	O
Interactions	O
Although	O
in	O
vitro	O
studies	O
demonstrated	O
the	O
potential	O
of	O
rifaximin	B-Drug
to	O
interact	O
with	O
cytochrome	O
P9	O
9A9	O
(	O
CYP9A9	O
)	O
a	O
clinical	O
drug	O
-	O
drug	O
interaction	O
study	O
demonstrated	O
that	O
rifaximin	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
midazolam	B-Drug
either	O
presystemically	O
or	O
systemically	O
.	O
      
Concomitant	O
administration	O
of	O
a	O
loop	B-Group
diuretic	I-Group
had	O
no	O
effect	O
on	O
the	O
calcium	O
-	O
lowering	O
action	O
of	O
Aredia	B-Brand
.	O
      
Oral	O
contraceptives	B-Group
containing	O
estrogen	B-Drug
:	O
tetracyclines	B-Group
may	O
decrease	O
the	O
contraceptive	O
effect	O
and	O
increase	O
the	O
chance	O
of	O
unwanted	O
pregnancy	O
.	O
      
Not	O
compatible	O
with	O
CNS	B-Group
depressants	I-Group
or	O
trycyclic	B-Group
antidepressants	I-Group
      
The	O
contribution	O
of	O
vincristine	B-Drug
sulfate	I-Drug
to	O
this	O
interaction	O
is	O
not	O
certain	O
.	O
      
No	O
reported	O
significant	O
interactions	O
      
LUCENTIS	B-Brand
intravitreal	O
injection	O
has	O
been	O
used	O
adjunctively	O
with	O
verteporfin	B-Drug
photodynamic	O
therapy	O
(	O
PDT	O
)	O
.	O
      
May	O
increase	O
the	O
effect	O
of	O
oral	O
blood	B-Group
thinners	I-Group
for	O
example	O
warfarin	B-Drug
(	O
Coumadin	B-Brand
)	O
.	O
      
Warfarin	B-Drug
:	O
Sparfloxacin	B-Drug
does	O
not	O
increase	O
the	O
anti	O
-	O
coagulant	O
effect	O
of	O
warfarin	B-Drug
.	O
      
Dosage	O
adjustment	O
should	O
be	O
based	O
on	O
serial	O
blood	O
level	O
monitoring	O
.	O
      
Also	O
see	O
CLINICAL	O
PHARMACOLOGY	O
      
There	O
have	O
been	O
no	O
studies	O
of	O
the	O
interaction	O
of	O
methyl	B-Drug
aminolevulinate	I-Drug
cream	O
with	O
any	O
other	O
drugs	O
including	O
local	O
anesthetics	B-Group
.	O
      
It	O
is	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
known	O
photosensitizing	O
agents	O
might	O
increase	O
the	O
photosensitivity	O
reaction	O
of	O
actinic	O
keratoses	O
treated	O
with	O
methyl	B-Drug
aminolevulinate	I-Drug
cream	O
.	O
      
No	O
drug	O
interaction	O
studies	O
were	O
conducted	O
.	O
      
